PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NFLOXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD1yLkCyNlc3KM7:TR?= M3X6XXNCVkeHUh?=
CHP-212 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLaTWM2OD1yLkCyPFg2KM7:TR?= M1XZT3NCVkeHUh?=
EoL-1-cell NYPZS3RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nGUmlEPTB;MD6wOFE2OiEQvF2= MWfTRW5ITVJ?
DU-4475 M{fBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfuT|NKSzVyPUCuNFc2QTlizszN MUXTRW5ITVJ?
MMAC-SF M{jrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TJVGlEPTB;MD6xNFk4PCEQvF2= NUnNToFCW0GQR1XS
AGS MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf5UW9EUUN3ME2wMlEyPzF|IN88US=> NGTPS3RUSU6JRWK=
M14 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMUW0Olgh|ryP NGfDd|FUSU6JRWK=
CP50-MEL-B NVG1cJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUeyOVQh|ryP NETGNnJUSU6JRWK=
C32 M3zCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XRTGlEPTB;MD6xPVA4OiEQvF2= M2jvdHNCVkeHUh?=
KMOE-2 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;pXmlEPTB;MD6xPVc6PSEQvF2= M1zQRnNCVkeHUh?=
A101D NWWwS5VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDPTWM2OD1yLkKxOEDPxE1? NX\y[phKW0GQR1XS
KM12 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq5UFR7UUN3ME2wMlI1ODV5IN88US=> M4fqc3NCVkeHUh?=
HSC-4 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMkSzPVUh|ryP NFjSUplUSU6JRWK=
NOMO-1 NF7mTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMkW3OFIh|ryP NYrDb25SW0GQR1XS
MZ7-mel MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37MTWlEPTB;MD6yOlM1KM7:TR?= NEjGd4VUSU6JRWK=
ACN NGHYSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ZXotKSzVyPUCuNlY4OzdizszN MV7TRW5ITVJ?
MEL-HO M4qyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMke2OVIh|ryP Ml;yV2FPT0WU
BHT-101 NUHLZ2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;kbYhKSzVyPUCuNlg3ODZizszN MlflV2FPT0WU
SK-MEL-28 M3fITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHBN2RbUUN3ME2wMlMxPDB7IN88US=> MYXTRW5ITVJ?
KG-1 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG3TWM2OD1yLkOwOlY5KM7:TR?= NEmxdGRUSU6JRWK=
COLO-679 MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwM{K3NkDPxE1? M3TCfnNCVkeHUh?=
SK-MEL-24 NUj0eVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEThdlBKSzVyPUCuN|I5OTNizszN MYTTRW5ITVJ?
G-361 M4izNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfCcnVEUUN3ME2wMlM3Pzl3IN88US=> MWjTRW5ITVJ?
KY821 NWHOcHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nhXGlEPTB;MD6zO|kyKM7:TR?= M3v5[XNCVkeHUh?=
KASUMI-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPRTWM2OD1yLkO5PUDPxE1? MUTTRW5ITVJ?
HL-60 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XHe2lEPTB;MD60NVExPyEQvF2= NGjRW5FUSU6JRWK=
K5 NGLGZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNEOxNVch|ryP MU\TRW5ITVJ?
KU812 NY\YephoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjZ[4tKSzVyPUCuOFUzQTlizszN M1m1V3NCVkeHUh?=
SH-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwNE[yOVYh|ryP MUDTRW5ITVJ?
HTC-C3 NV\JT5N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fFbmlEPTB;MD60OlU{OSEQvF2= M4jsWnNCVkeHUh?=
CP66-MEL NHLYS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwNEi4NFkh|ryP NX:5c49MW0GQR1XS
WM-115 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\tTWM2OD1yLkS5NlU4KM7:TR?= NWCzbZVZW0GQR1XS
A2780 NITIZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j6OmlEPTB;MD60PVgzOyEQvF2= NXPXZ3E3W0GQR1XS
P12-ICHIKAWA NELTTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwNkGyNlEh|ryP NVz4TYpyW0GQR1XS
HMV-II M1PRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfsWZlZUUN3ME2wMlY1PDZ3IN88US=> MkX1V2FPT0WU
HT-144 NH\GdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwNkS2OVch|ryP Ml3CV2FPT0WU
LB2518-MEL NFmzVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzCcJRrUUN3ME2wMlcyPjN{IN88US=> MVrTRW5ITVJ?
NCI-SNU-1 M{HkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwN{W0N|Mh|ryP NXrHcHdrW0GQR1XS
C2BBe1 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0fWlEPTB;MD64NVAzOyEQvF2= M2K2NnNCVkeHUh?=
PSN1 NUK5N2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6yTWM2OD1yLkm2NVk3KM7:TR?= NUnaemJuW0GQR1XS
UACC-257 NGXNO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwOU[0O|Mh|ryP MYfTRW5ITVJ?
RVH-421 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LDPGlEPTB;MD65O|E5KM7:TR?= M2DySnNCVkeHUh?=
GP5d MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DVeWlEPTB;MD65PFMxQCEQvF2= M1HD[HNCVkeHUh?=
TYK-nu NFvWfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLETWM2OD1zLkCzNVczKM7:TR?= NGK2O4xUSU6JRWK=
SK-N-AS M{\VU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwMEe5OFch|ryP NV3VZnRxW0GQR1XS
SW620 M{n0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMUO1N|Qh|ryP MVrTRW5ITVJ?
HuP-T4 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\QWVBDUUN3ME2xMlE5OzV7IN88US=> NULlfGpXW0GQR1XS
A549 NVqyUGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfB[phTUUN3ME2xMlE6PTd4IN88US=> Mmn5V2FPT0WU
Mewo MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq0co1KSzVyPUGuNlAzPzZizszN M3LGO3NCVkeHUh?=
ONS-76 M2C1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LRbmlEPTB;MT6yNlA1QSEQvF2= Moq2V2FPT0WU
SK-MEL-1 M{X1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwMkO0NVkh|ryP M2GwZ3NCVkeHUh?=
RCM-1 NEDFdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PZWWlEPTB;MT6yOFA1PyEQvF2= MY\TRW5ITVJ?
H-EMC-SS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\RRVVKSzVyPUGuNlk3ODhizszN MnLQV2FPT0WU
NCI-H2291 M2HPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm2UYNKSzVyPUGuN|I2OzZizszN MnHaV2FPT0WU
SW1463 M2HS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwM{O3NlEh|ryP M3T6XXNCVkeHUh?=
LS-411N MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTsTWM2OD1zLkSwOVE4KM7:TR?= M{Gy[3NCVkeHUh?=
BV-173 M{fY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPlTWM2OD1zLkS0NFE2KM7:TR?= MV3TRW5ITVJ?
LS-513 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP0TWM2OD1zLkS1NVkzKM7:TR?= M13pdnNCVkeHUh?=
LoVo M3L5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwNE[zPVkh|ryP M2DoTnNCVkeHUh?=
HO-1-N-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m4fmlEPTB;MT61NVY{PCEQvF2= NH;0OYdUSU6JRWK=
ML-2 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvsOFhKSzVyPUGuOVI5PjhizszN MkPzV2FPT0WU
NCI-H1437 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwNUWyO|Uh|ryP M33E[3NCVkeHUh?=
SW1116 NUfhVpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmwSWtKSzVyPUGuOVY{QThizszN NW\EXIs6W0GQR1XS
A4-Fuk MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe1TWM2OD1zLkW3NFQ2KM7:TR?= MojlV2FPT0WU
HD-MY-Z M3vo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTHTWM2OD1zLkW3N|c3KM7:TR?= NGfERlNUSU6JRWK=
SK-MEL-2 M3ficGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwNUe0OVkh|ryP NWPl[owxW0GQR1XS
RT-112 M4TEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LicWlEPTB;MT61PFk2OiEQvF2= M3;BOHNCVkeHUh?=
COLO-829 NEnqR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwNkKyN|Ih|ryP M3i3W3NCVkeHUh?=
OVCAR-5 NX\CeG1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXvTWM2OD1zLke3Olg4KM7:TR?= NUS0S2lSW0GQR1XS
NB69 M2jOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K4eWlEPTB;MT63PFQ3QSEQvF2= MorEV2FPT0WU
NCI-H292 M2[5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfJ[mpbUUN3ME2xMlg3Pjl7IN88US=> M2qybnNCVkeHUh?=
LOXIMVI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\MTWM2OD1zLki5OFI4KM7:TR?= NILlNXJUSU6JRWK=
BPH-1 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWwWpdzUUN3ME2xMlg6PTlzIN88US=> MmDTV2FPT0WU
A375 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KzOWlEPTB;MT64PVcyPCEQvF2= NVvGVHRiW0GQR1XS
LCLC-97TM1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGTWM2OD1zLkmyNlU3KM7:TR?= MWjTRW5ITVJ?
RXF393 NEnndY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXzW5hsUUN3ME2xMlk4QDh5IN88US=> NVLR[VJ1W0GQR1XS
HCC70 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXuyVZhSUUN3ME2yMlAzPDJ4IN88US=> MlfoV2FPT0WU
EM-2 NVqz[Y9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PvWGlEPTB;Mj6wO|E6QCEQvF2= MlqxV2FPT0WU
MZ2-MEL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m4eWlEPTB;Mj6xNVEzPyEQvF2= MoTuV2FPT0WU
HN M3rzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvUTWM2OD1{LkG2Nlc5KM7:TR?= NWHI[|dbW0GQR1XS
A2058 NEfj[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2wcnlJUUN3ME2yMlE6Ojd7IN88US=> NWDneWU1W0GQR1XS
NB7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwM{SwPFYh|ryP MorrV2FPT0WU
DOK NIWxelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7xc5lKSzVyPUKuN|U4PzNizszN MmnKV2FPT0WU
CAL-27 NV6wZZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTJTWM2OD1{LkO5NlM3KM7:TR?= NUDCOIJ3W0GQR1XS
BB65-RCC M3Hofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILHeIZKSzVyPUKuOFA3PzRizszN NHPCbI9USU6JRWK=
RD NX7kZ49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fXVGlEPTB;Mj60OFczOyEQvF2= NUK5U2c3W0GQR1XS
KNS-62 NUjvVoxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDYcmdKSzVyPUKuOVEyPjRizszN NUHT[GtwW0GQR1XS
EW-13 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnPd3hYUUN3ME2yMlU3OzN7IN88US=> MkTVV2FPT0WU
DB M{Dq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzBN2hyUUN3ME2yMlU5Pzh6IN88US=> NETyZ2ZUSU6JRWK=
HCC2218 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTQTWM2OD1{Lk[0O|c5KM7:TR?= M1z3RXNCVkeHUh?=
L-363 NHezc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHFTWM2OD1{Lke0N|ch|ryP M3jaWnNCVkeHUh?=
CHL-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXez[lVrUUN3ME2yMlgxPzh3IN88US=> MUPTRW5ITVJ?
BFTC-905 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTFTWM2OD1{LkiyOVMh|ryP M4XLenNCVkeHUh?=
HCE-T NIf6VVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPkSm9PUUN3ME2yMlg{OjZ2IN88US=> NYjMNHFbW0GQR1XS
COLO-792 NIr1WGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7zO5hKSzVyPUKuPFQxOjdizszN NXrEe2NWW0GQR1XS
LB2241-RCC Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXMNlV2UUN3ME2yMlg2QDl|IN88US=> M1LsdXNCVkeHUh?=
CAL-39 M4TpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwOEm5PVkh|ryP NIPCR3VUSU6JRWK=
T-24 M3zUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2izWmlEPTB;Mj65NVEyOiEQvF2= NVj3UmVJW0GQR1XS
NCI-H727 M3uxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojiTWM2OD1{LkmxO|k3KM7:TR?= NECzSYRUSU6JRWK=
Ca9-22 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr5TWM2OD1{Lkm3NlU2KM7:TR?= NYLtWFU5W0GQR1XS
MIA-PaCa-2 M1:wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwMEC3PFEh|ryP MXTTRW5ITVJ?
HT-1080 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\OcGRKSzVyPUOuNFE6QTdizszN NVLVS3Z{W0GQR1XS
D-423MG Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17P[GlEPTB;Mz6wO|c2OyEQvF2= MUXTRW5ITVJ?
LAMA-84 NUixfmJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P3VmlEPTB;Mz6xN|U5KM7:TR?= M2\IdXNCVkeHUh?=
SW780 NY\NeHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXBTWM2OD1|LkG0NlI6KM7:TR?= MlS3V2FPT0WU
KU-19-19 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OwPWlEPTB;Mz6xO|A{PCEQvF2= NWXpTGRjW0GQR1XS
COLO-741 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PqNWlEPTB;Mz6xPFY4OyEQvF2= NWHYbYM1W0GQR1XS
HSC-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn6XnlKSzVyPUOuNlMyPTFizszN NYK2cJN6W0GQR1XS
SN12C MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XOOWlEPTB;Mz6yOFcxOSEQvF2= NEn0c|dUSU6JRWK=
786-0 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPZTFFzUUN3ME2zMlI4OjR|IN88US=> M2n4eXNCVkeHUh?=
GAK M2HQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13JSWlEPTB;Mz6zNlU3OSEQvF2= NFPRe5pUSU6JRWK=
PANC-03-27 M2LCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTNwM{WwOFUh|ryP M13B[XNCVkeHUh?=
CTB-1 NIfxZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX4O4hrUUN3ME2zMlQ4ODR5IN88US=> Mk\4V2FPT0WU
A427 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwNUm1OVYh|ryP NX\xOXc4W0GQR1XS
EGI-1 M1PaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW3TWM2OD1|Lk[wOVg{KM7:TR?= NHf0fZpUSU6JRWK=
U-2-OS NIHzR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrsTWM2OD1|Lk[3NlU3KM7:TR?= NX;rd45sW0GQR1XS
NCI-SNU-5 NGrVZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnScINKSzVyPUOuOlc4OyEQvF2= MVfTRW5ITVJ?
SK-LU-1 M3HneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfuOoNUUUN3ME2zMlY5Pzl6IN88US=> MoG3V2FPT0WU
697 NV7BTYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DPN2lEPTB;Mz62PVYxOyEQvF2= MYDTRW5ITVJ?
HPAF-II MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2yTWM2OD1|Lke1OFkh|ryP Mlz4V2FPT0WU
NCI-H2087 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M12xUWlEPTB;Mz64OFY4OiEQvF2= MlfwV2FPT0WU
SK-MEL-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rWV2lEPTB;Mz64OVE2PCEQvF2= MYPTRW5ITVJ?
CGTH-W-1 M2PkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwOEW3NlUh|ryP M3jvd3NCVkeHUh?=
8505C NGLCdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLTWM2OD1|LkmwNFc5KM7:TR?= M3rXS3NCVkeHUh?=
GAMG NVPQd4VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn6V3lKSzVyPUSuNFI{PzdizszN MlHiV2FPT0WU
SW626 M1rqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO5TWM2OD12LkC0OFgh|ryP NInHNlJUSU6JRWK=
CAL-62 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WzWWlEPTB;ND6wO|Q{KM7:TR?= MlnxV2FPT0WU
MHH-PREB-1 NIrrVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH3fGZKSzVyPUSuNVIyOTFizszN NEPDVmlUSU6JRWK=
RPMI-7951 M3TTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TZUGlEPTB;ND6yOVU5QSEQvF2= NEDXWoRUSU6JRWK=
HOP-92 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwMkW2O{DPxE1? MlvoV2FPT0WU
MDA-MB-231 NXj6Vo5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XtWmlEPTB;ND6yPVIzOyEQvF2= MVLTRW5ITVJ?
LAN-6 NFi1dWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M360bGlEPTB;ND6zNVY{PyEQvF2= NFz1fHdUSU6JRWK=
ALL-PO NHr1TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzMbFFKSzVyPUSuN|YyPTZizszN MXXTRW5ITVJ?
HH NWLSeJl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnv[ohKSzVyPUSuOFE2QTdizszN NWjSe2dbW0GQR1XS
IGROV-1 NHnm[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn5[nlKSzVyPUSuOFUyPzFizszN NU\GWFNmW0GQR1XS
NCI-H358 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nQe2lEPTB;ND60OVM5PSEQvF2= MkHQV2FPT0WU
NB5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hy[mlEPTB;ND62NFM3QSEQvF2= NFnpOXZUSU6JRWK=
NCI-H747 NVHjUlNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwNki4NFch|ryP MYPTRW5ITVJ?
NH-12 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPPOVBUUUN3ME20MlcyPjJ3IN88US=> M3LsZXNCVkeHUh?=
LB1047-RCC NEjyV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnVeXVKSzVyPUSuO|M5OTVizszN MV\TRW5ITVJ?
EFO-27 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjJTWM2OD12Lke4OlY4KM7:TR?= M37xdnNCVkeHUh?=
EPLC-272H MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDnTWM2OD12Lkm5OlY6KM7:TR?= MVHTRW5ITVJ?
CAL-54 NYixemNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjiTWM2OD13LkCyOlk2KM7:TR?= NGexc45USU6JRWK=
H4 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ISWlEPTB;NT6wOFI2PSEQvF2= M2TIeXNCVkeHUh?=
MOLT-13 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrlUYNKUUN3ME21MlA3Pzd4IN88US=> NEjNVpNUSU6JRWK=
CAL-33 NYPqXHYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzv[os5UUN3ME21MlEzOzF5IN88US=> MXjTRW5ITVJ?
23132-87 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVwMU[4O|Ih|ryP M1\2V3NCVkeHUh?=
UM-UC-3 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTVwMUiwOFch|ryP MX3TRW5ITVJ?
HuH-7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwMkexOFch|ryP Ml\qV2FPT0WU
BCPAP M{nsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz3TWM2OD13LkOyPVY6KM7:TR?= NGHIbIxUSU6JRWK=
AsPC-1 NEPuVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLmTWM2OD13LkO2O|Y{KM7:TR?= MmfLV2FPT0WU
NCI-H1155 M4q1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmT3RxUUN3ME21MlQxODVzIN88US=> Mny2V2FPT0WU
GT3TKB MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\r[HJKSzVyPUWuOFY2QThizszN MVnTRW5ITVJ?
HCC2998 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV71fGxQUUN3ME21MlQ6OTB7IN88US=> M3T4XXNCVkeHUh?=
NUGC-3 NIjNRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrQTWM2OD13LkS5N|AzKM7:TR?= NH\zVXNUSU6JRWK=
Hs-578-T NH3DTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jOUGlEPTB;NT61N|c6PCEQvF2= MY\TRW5ITVJ?
FADU M3nNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jkb2lEPTB;NT61OVczPiEQvF2= M3;WVXNCVkeHUh?=
NBsusSR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[5TWM2OD13LkW3NVU2KM7:TR?= MXLTRW5ITVJ?
ME-180 M4TSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOyTWM2OD13LkW4NFkzKM7:TR?= M2jsS3NCVkeHUh?=
SW1710 NInsXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnw[HV1UUN3ME21MlYyPjV2IN88US=> NHvaem1USU6JRWK=
HuP-T3 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvqRXF4UUN3ME21MlYzODJ7IN88US=> MmH5V2FPT0WU
HOS M4TMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHtTWM2OD13Lk[yPVI{KM7:TR?= M2WxNXNCVkeHUh?=
PA-1 M{fuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O0WGlEPTB;NT62OFI3PSEQvF2= M{j3bnNCVkeHUh?=
LU-99A MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjwUW9KSzVyPUWuOlY1PTFizszN MXXTRW5ITVJ?
RS4-11 NEXxS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:0TWM2OD13Lk[2O|c2KM7:TR?= NHvzfYVUSU6JRWK=
TE-8 NV3qSohUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwNki1N|ch|ryP NWG3XIxIW0GQR1XS
RERF-LC-MS M3zS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fO[mlEPTB;NT62PFgxOyEQvF2= NF23SZJUSU6JRWK=
MEL-JUSO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXTXGFKSzVyPUWuO|M4QCEQvF2= NYCwN5p4W0GQR1XS
SK-MES-1 M{m1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLuU|JPUUN3ME21Mlg{PTJ6IN88US=> NWHwSZI1W0GQR1XS
D-263MG MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwOEizOVEh|ryP MlyyV2FPT0WU
NB10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHtXWd2UUN3ME21Mlg6PDZizszN NInTPWVUSU6JRWK=
SK-HEP-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jxW2lEPTB;NT65N|Q4OSEQvF2= NHTPO3pUSU6JRWK=
HT-29 NWi4fpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTDXmJDUUN3ME21Mlk5OTF6IN88US=> NXnOVI9LW0GQR1XS
KYSE-140 NFXpZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rPdGlEPTB;Nj6wNlE5OiEQvF2= M4q1R3NCVkeHUh?=
NCI-H1666 NXTu[45xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;TV2lEPTB;Nj6wPFQ3OSEQvF2= MVXTRW5ITVJ?
NCI-H1304 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkeyTWM2OD14LkG5PVQh|ryP M3y1fXNCVkeHUh?=
RPMI-8866 NFzhcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjPVoRKSzVyPU[uNlE{OTNizszN M2L6e3NCVkeHUh?=
MV-4-11 M{HTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSyeotKSzVyPU[uNlMyQTlizszN NV;tenA3W0GQR1XS
A431 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTRRmpKSzVyPU[uNlQzQTZizszN M{LY[nNCVkeHUh?=
PANC-10-05 M2jzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjZTWM2OD14LkK4N|Y{KM7:TR?= M{DLdHNCVkeHUh?=
TK10 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37yRWlEPTB;Nj6zNlYxPCEQvF2= NXLm[5l3W0GQR1XS
NCI-H1975 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTZwNEeyNVUh|ryP NIXLT2pUSU6JRWK=
A172 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwNEmxO|Yh|ryP NYTsNZRUW0GQR1XS
D-566MG M4L4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrvTFlKSzVyPU[uOVQ{ODNizszN NGnLW45USU6JRWK=
NCI-H2122 M3X2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPTXoJKSzVyPU[uOlE2OjhizszN MkHnV2FPT0WU
COR-L105 M3HybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHlTWM2OD14Lk[1Nlc2KM7:TR?= NI\OW3NUSU6JRWK=
AN3-CA Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPBe5dKSzVyPU[uOlg3PDFizszN Mkj0V2FPT0WU
Calu-6 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XHOmlEPTB;Nj63PVY6QCEQvF2= MX3TRW5ITVJ?
HCT-116 NFezTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC2TWM2OD14LkixNlY1KM7:TR?= MVLTRW5ITVJ?
MHH-NB-11 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjqZZFKSzVyPU[uPFUxODJizszN MWDTRW5ITVJ?
MFE-280 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnvTIdIUUN3ME22Mlg2QTh|IN88US=> NX\mfWIzW0GQR1XS
SW1088 NI[4cYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[zOGlEPTB;Nj65NVkyOyEQvF2= MortV2FPT0WU
SW48 M1nmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYeVlIUUN3ME22Mlk1PTFizszN M{XOZ3NCVkeHUh?=
HuCCT1 NWHoZWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvXb|BKSzVyPUeuNFExOzdizszN MVHTRW5ITVJ?
ACHN NHHDVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTdwMEK5OFMh|ryP MVvTRW5ITVJ?
8305C MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTwe4RoUUN3ME23MlA6QTl3IN88US=> Mnf5V2FPT0WU
DoTc2-4510 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTdwMUKxOUDPxE1? MWjTRW5ITVJ?
COR-L23 NIDRNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX6VohKSzVyPUeuNlQ1OiEQvF2= M3XNNHNCVkeHUh?=
SK-MEL-30 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi3XGVKSzVyPUeuNlUxQDNizszN MofTV2FPT0WU
BE-13 NXnHVFN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjZblZXUUN3ME23MlM{QDN2IN88US=> NX7YNYVNW0GQR1XS
GR-ST M1rnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOw[WFKSzVyPUeuOFAyPzRizszN NYi5c5VWW0GQR1XS
LU-135 NV;1[mVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W4S2lEPTB;Nz61OVk{QSEQvF2= NVnYOYN5W0GQR1XS
U-266 NVPYUXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\jTVZxUUN3ME23MlU3Ojh4IN88US=> MnG5V2FPT0WU
NCI-H1355 M33tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLsVohCUUN3ME23MlU5PjN3IN88US=> NI\DbFRUSU6JRWK=
NB14 M3TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzCSXFnUUN3ME23MlY3PjR{IN88US=> NHPWdlZUSU6JRWK=
SCC-25 NXXKcZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnjTWM2OD15LkewPUDPxE1? M{LzfHNCVkeHUh?=
COLO-678 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTdwN{GwO|Yh|ryP NYfUUmtXW0GQR1XS
TGBC1TKB NVjCZVhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD15Lki5N|k5KM7:TR?= NG\teHNUSU6JRWK=
IST-MEL1 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vtWWlEPTB;OD6wNFQxPiEQvF2= NUTr[Ih4W0GQR1XS
ECC10 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[3PGlEPTB;OD6wN|M6PSEQvF2= MUXTRW5ITVJ?
EW-16 M4n3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\hXGdGUUN3ME24MlA5PDR3IN88US=> NVLwRWV3W0GQR1XS
DOHH-2 NYTWdFR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRThwMkCwPVUh|ryP MVnTRW5ITVJ?
NCI-H1581 NEHTe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDRSINKSzVyPUiuNlY{OjNizszN MXXTRW5ITVJ?
TE-5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwNEK0Nlkh|ryP M{LLT3NCVkeHUh?=
CAKI-1 NXLPR3VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG2TWM2OD16LkW3NlIzKM7:TR?= NEHsZoRUSU6JRWK=
A673 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfEXHNKSzVyPUiuOlMzODJizszN MWTTRW5ITVJ?
CAL-12T M2DMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRThwNkW3OVMh|ryP MUDTRW5ITVJ?
DBTRG-05MG NG\EXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrj[mN3UUN3ME24Mlc1QDV7IN88US=> MXXTRW5ITVJ?
SK-N-FI NWP6dmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rPcWlEPTB;OD64NVM4QSEQvF2= Mme2V2FPT0WU
K-562 Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHsZoNKSzVyPUiuPFM6PTdizszN M1fnUXNCVkeHUh?=
SBC-1 NYi5[3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0W3dKSzVyPUiuPFY3PDVizszN MULTRW5ITVJ?
ES4 M2TiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD16Lki2PFg1KM7:TR?= NGrMeo5USU6JRWK=
MS-1 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\JRmlEPTB;OD64O|UyPyEQvF2= M2exSXNCVkeHUh?=
RKO NXPDeWx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jMbWlEPTB;OD64PVA2PyEQvF2= MmnwV2FPT0WU
NCI-H1693 NEn6[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH24cVZKSzVyPUiuPVIyPyEQvF2= MoLqV2FPT0WU
SW954 M3vDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETxTm1KSzVyPUiuPVY6PzhizszN Ml[1V2FPT0WU
SK-UT-1 NFLadXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLaTWM2OD16Lkm3Olg{KM7:TR?= NWDVbXVSW0GQR1XS
T98G NVXpVpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5cWt1UUN3ME24Mlk6QDR4IN88US=> M{DLXXNCVkeHUh?=
NCI-H2126 M1y2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LjWmlEPTB;OT6wNFgzPiEQvF2= M4LJNXNCVkeHUh?=
TE-12 NWP5WHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrHc|N2UUN3ME25MlA{OzZ5IN88US=> Mn7PV2FPT0WU
DK-MG Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{npcWlEPTB;OT6yNVE6OSEQvF2= NYroRZN4W0GQR1XS
MEG-01 NWjwWGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTlwMkS5N|Eh|ryP NEKycHhUSU6JRWK=
HCC1937 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTlwMkmwPVEh|ryP NWrs[G1uW0GQR1XS
MKN45 NV6zempRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC5TWM2OD17LkS1NFY2KM7:TR?= Ml3tV2FPT0WU
NCI-H1792 M3ztc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTlwNEWyNVkh|ryP MV\TRW5ITVJ?
SW1417 MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLJS3NKSzVyPUmuOVY5OzdizszN NGrtSGtUSU6JRWK=
639-V MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTlwNkSzPFgh|ryP NXOxXnJOW0GQR1XS
P30-OHK NIfoblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XXOWlEPTB;OT62OVMyPiEQvF2= NWLLV2tIW0GQR1XS
YKG-1 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XBUWlEPTB;OT63OVA{OyEQvF2= NXrEelB6W0GQR1XS
KGN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTlwOEO3PVUh|ryP NX3wdIFJW0GQR1XS
MSTO-211H MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3oTWM2OD17Lkm1OVI6KM7:TR?= NFrtVHhUSU6JRWK=
NCI-H1573 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5RYl2UUN3ME2xNE4yPTd2IN88US=> MnzTV2FPT0WU
NCI-H720 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFyLkG5PFkh|ryP NInkfFJUSU6JRWK=
KARPAS-45 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWzdoJKSzVyPUGwMlI4QTVizszN MmHxV2FPT0WU
MDA-MB-175-VII NFrxc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPl[m9pUUN3ME2xNE41QCEQvF2= NEX4VGxUSU6JRWK=
SK-NEP-1 NXrPeVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zRSmlEPTB;MUCuOFk5OSEQvF2= NFiyVllUSU6JRWK=
MKN28 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HtOGlEPTB;MUCuOVE5KM7:TR?= MkL0V2FPT0WU
KYSE-520 NY\pT|k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4TWM2OD1zMD61NkDPxE1? NYXQZmFpW0GQR1XS
KE-37 M4XPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3oTWM2OD1zMD61NlczKM7:TR?= MUPTRW5ITVJ?
VA-ES-BJ M1PObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ztOGlEPTB;MUCuOVY4KM7:TR?= NXLYXHEzW0GQR1XS
CCRF-CEM M1fSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFyLkW2PFQh|ryP M4ruOHNCVkeHUh?=
GMS-10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKwOYdKSzVyPUGwMlYxQTRizszN M2exOHNCVkeHUh?=
NCI-H1623 NFrpV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDnUGpqUUN3ME2xNE43Ozd7IN88US=> NWfkXFlGW0GQR1XS
NEC8 M2jVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFyLke3O|Mh|ryP MXnTRW5ITVJ?
MOLT-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImxbW5KSzVyPUGwMlgyOTNizszN MkLDV2FPT0WU
DJM-1 NET2fJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLsR4FpUUN3ME2xNU4xOzd7IN88US=> M2jxUXNCVkeHUh?=
U251 M4\x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLtTWM2OD1zMT6wOFIh|ryP NEL1cHdUSU6JRWK=
SBC-5 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfiTGJrUUN3ME2xNU4yPDZ5IN88US=> M37lS3NCVkeHUh?=
SW756 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFzLkKxOVQh|ryP M1uyXHNCVkeHUh?=
KS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fjOGlEPTB;MUGuNlYyQSEQvF2= NGXPZ5ZUSU6JRWK=
SF295 MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFzLkOxNFQh|ryP Mn\PV2FPT0WU
YH-13 NFXNZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fGb2lEPTB;MUGuN|I3PyEQvF2= NIDNdGtUSU6JRWK=
SW837 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fYWGlEPTB;MUGuN|UxPiEQvF2= NWLEXVd7W0GQR1XS
KYSE-450 NEfjfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf2TWM2OD1zMT60NFU4KM7:TR?= NUOyfFJWW0GQR1XS
KYSE-180 M3fqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjr[ItKSzVyPUGxMlQ5OiEQvF2= M2PHOnNCVkeHUh?=
S-117 NVj3NZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPDTXdKSzVyPUGxMlQ5QTZizszN NYXxZ2FqW0GQR1XS
KOSC-2 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLNGlEPTB;MUGuOlIzOiEQvF2= NWLMSIpSW0GQR1XS
KYSE-270 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFzLki3OFUh|ryP MmfUV2FPT0WU
D-336MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFzLkmwO|Uh|ryP NG\C[3FUSU6JRWK=
KALS-1 NUOzPGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLRUGpSUUN3ME2xNk4xODF4IN88US=> NVrEcmw5W0GQR1XS
LB373-MEL-D Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLTTWM2OD1zMj6wOVM{KM7:TR?= MUDTRW5ITVJ?
HLE M4TxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7pTWM2OD1zMj6wOVg2KM7:TR?= M4D1dHNCVkeHUh?=
SJSA-1 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmwepVYUUN3ME2xNk4xPzN3IN88US=> MXfTRW5ITVJ?
SW1990 M3[w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\4TWM2OD1zMj6wPVEyKM7:TR?= MULTRW5ITVJ?
NOS-1 NHHPPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLSTWM2OD1zMj6xN|UzKM7:TR?= M3n2TXNCVkeHUh?=
GI-ME-N MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nOdGlEPTB;MUKuNlE3OyEQvF2= MYnTRW5ITVJ?
NCI-H1703 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWixTIlsUUN3ME2xNk4zPjF4IN88US=> M3fxcXNCVkeHUh?=
ES7 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv1OGpKSzVyPUGyMlI4OjRizszN NEjWSndUSU6JRWK=
KYSE-510 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmy[ndHUUN3ME2xNk42ODd7IN88US=> M2PzW3NCVkeHUh?=
BHY MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF{LkWzNFch|ryP NHO5eItUSU6JRWK=
TCCSUP NWnYbXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn0TWM2OD1zMj61O|U4KM7:TR?= NUnEWHE6W0GQR1XS
HSC-2 NF2yPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF{LkW5PVYh|ryP NXX6c3ljW0GQR1XS
BEN M{PQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\kWoJiUUN3ME2xNk43OTR|IN88US=> M3Pkc3NCVkeHUh?=
769-P Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m4RWlEPTB;MUKuO|kzPCEQvF2= NVnVR5JnW0GQR1XS
HT M3PL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTUTWM2OD1zMj64N|Q3KM7:TR?= Mlq3V2FPT0WU
LXF-289 NFXJT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:ycGlEPTB;MUKuPVU{OSEQvF2= MV7TRW5ITVJ?
OVCAR-3 NUjOZVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF{Lkm1Olch|ryP NUj2cFZHW0GQR1XS
ATN-1 NFTKWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TSb2lEPTB;MUOuNFE5PCEQvF2= M17WVXNCVkeHUh?=
8-MG-BA Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jTNmlEPTB;MUOuNFQ2PSEQvF2= NFjMcHhUSU6JRWK=
SW13 NFf6RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\uOJdKSzVyPUGzMlEyPjVizszN NWjVdllKW0GQR1XS
NCI-H1092 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF|LkG2NkDPxE1? NV;GXXVkW0GQR1XS
OAW-42 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7rTWM2OD1zMz6xPVM4KM7:TR?= NF24fFhUSU6JRWK=
NCI-H2452 NH\FNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjEXY9VUUN3ME2xN{4zOTd3IN88US=> NUWxZ402W0GQR1XS
CAPAN-1 NHfUbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfpfmxKSzVyPUGzMlU2OTRizszN Mk\aV2FPT0WU
NCI-H2009 NF3zdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKzfW5ZUUN3ME2xN{42QTF7IN88US=> NUH4TnNUW0GQR1XS
SF268 NFnudlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF|Lk[zNlYh|ryP MV7TRW5ITVJ?
GCIY NEnLSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnUdlNKSzVyPUGzMlY6OjdizszN MonqV2FPT0WU
OS-RC-2 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHxTWM2OD1zMz65OVAyKM7:TR?= MoLwV2FPT0WU
GCT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0bI1jUUN3ME2xN{46Pjl5IN88US=> M1;NeHNCVkeHUh?=
NB17 NF\uVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLIe5BKSzVyPUG0MlA5PSEQvF2= MWTTRW5ITVJ?
NCI-H2030 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLZTWM2OD1zND6xOFY2KM7:TR?= MlH2V2FPT0WU
HC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv4Z|k4UUN3ME2xOE4zODh5IN88US=> MVnTRW5ITVJ?
QIMR-WIL M3jWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13VNWlEPTB;MUSuN|QyOiEQvF2= NWjnUmZwW0GQR1XS
Capan-2 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXi[GZyUUN3ME2xOE4{PzF2IN88US=> MmfZV2FPT0WU
BALL-1 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\yUGlEPTB;MUSuOFY3PSEQvF2= M2PRfnNCVkeHUh?=
LS-1034 M4\uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjwV4hKSzVyPUG0MlYyPTJizszN MWTTRW5ITVJ?
U-118-MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzvZ5NKSzVyPUG0MlY{OSEQvF2= NU\aZ3ZUW0GQR1XS
NCI-H630 M4DkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF2Lk[1Olgh|ryP NUG0NG5RW0GQR1XS
OVCAR-8 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu1O4k6UUN3ME2xOE44OjBzIN88US=> MmPHV2FPT0WU
NCI-H2347 M4m5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF2LkiyN{DPxE1? NGqzfoVUSU6JRWK=
BT-549 NX;CS3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL3Nmh2UUN3ME2xOE45Ojh2IN88US=> NHziTYNUSU6JRWK=
LB831-BLC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF2Lki5N|Qh|ryP NVPZdG0zW0GQR1XS
NCI-H661 NUjYO|YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLpTWM2OD1zND65OVkh|ryP NV7kZ5BkW0GQR1XS
MKN7 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojETWM2OD1zNT6wNFk{KM7:TR?= NYfie5JSW0GQR1XS
U-87-MG M1XYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPrfYVKSzVyPUG1MlA5QTdizszN MWrTRW5ITVJ?
OVCAR-4 NYHHRlQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\WenlKSzVyPUG1MlE1OjRizszN NXvYZ41qW0GQR1XS
OE33 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPGXoJnUUN3ME2xOU4yPzFzIN88US=> NW\OT5NUW0GQR1XS
EC-GI-10 NF:2RY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLwdohKSzVyPUG1MlI{PTdizszN NV25RoFOW0GQR1XS
AM-38 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxR3dKSzVyPUG1MlI4OTdizszN NIDablhUSU6JRWK=
NCI-H1563 NUnFOJBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7rXlNKSzVyPUG1MlM1QSEQvF2= NGnBTHJUSU6JRWK=
SCC-4 NXrib|JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDtTWM2OD1zNT60NVA{KM7:TR?= M4fhRnNCVkeHUh?=
Detroit562 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF3LkS1OFch|ryP NGXRdWtUSU6JRWK=
PC-14 NIDFdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF3LkS4OlYh|ryP NWLUV3NHW0GQR1XS
ES3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrHWotKSzVyPUG1MlU{PiEQvF2= NHnnXW9USU6JRWK=
OCI-AML2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF3Lke2NVQh|ryP MXvTRW5ITVJ?
LU-134-A NWLITXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3LTWM2OD1zNT65NFE5KM7:TR?= NIDXcm5USU6JRWK=
SAS NYDEXlVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX1TWM2OD1zNT65N|c{KM7:TR?= NHvWWFZUSU6JRWK=
TGBC11TKB NXfWcpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF3Lkm0NVQh|ryP M37TTXNCVkeHUh?=
HOP-62 M3Sw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqzco12UUN3ME2xOU46PTl5IN88US=> NWm4T|dnW0GQR1XS
G-401 NHTrUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TMfmlEPTB;MUWuPVY1QSEQvF2= MVLTRW5ITVJ?
NCI-H28 NIHkdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF4LkC4OVYh|ryP MUXTRW5ITVJ?
A204 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvoTWM2OD1zNj6yNFA3KM7:TR?= NFrienFUSU6JRWK=
NCI-H1299 M124XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q3RmlEPTB;MU[uNlI6OSEQvF2= MoflV2FPT0WU
VMRC-RCZ NXywUHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTyW|JKSzVyPUG2MlI2QTJizszN Mn\aV2FPT0WU
BxPC-3 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF4LkK4OVYh|ryP M3;wVXNCVkeHUh?=
NCI-H2228 M{KySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe3NldyUUN3ME2xOk42OTV6IN88US=> NUHGV5JyW0GQR1XS
NCI-H23 M2LJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfoTWM2OD1zNj62NFc5KM7:TR?= MnjnV2FPT0WU
NKM-1 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF5LkCxPFkh|ryP NHu0SpJUSU6JRWK=
KYSE-70 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr2T2tpUUN3ME2xO{4zQDlizszN M2jjbHNCVkeHUh?=
BB49-HNC NXq2dnU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fwVGlEPTB;MUeuOVY5PiEQvF2= M1nafXNCVkeHUh?=
SCC-15 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHGNVdIUUN3ME2xO{45PDd|IN88US=> M2\F[3NCVkeHUh?=
D-247MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn5VIhKSzVyPUG3MlkzPDdizszN NWTiVldZW0GQR1XS
BB30-HNC NHfDOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\oUIFLUUN3ME2xPE4xOzF6IN88US=> MkLzV2FPT0WU
CAL-85-1 NEnTXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PrUmlEPTB;MUiuNVgxQSEQvF2= MlfoV2FPT0WU
HT-3 NYHYWXRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj3XnAyUUN3ME2xPE4{QTd5IN88US=> NX\oXXE1W0GQR1XS
KYSE-410 M1;VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PISWlEPTB;MUiuOFU4PyEQvF2= M{PmdnNCVkeHUh?=
SW982 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjDWVY2UUN3ME2xPE42PjR7IN88US=> NFr4T5dUSU6JRWK=
SW962 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF6LkW3NFIh|ryP M1zq[XNCVkeHUh?=
Ramos-2G6-4C10 M4\xSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TjXWlEPTB;MUiuOVkzPyEQvF2= NX7UUo1WW0GQR1XS
OC-314 NWfxdHBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DxeWlEPTB;MUiuO|M5PCEQvF2= MULTRW5ITVJ?
LS-123 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvnTWM2OD1zOD63PVAyKM7:TR?= MUfTRW5ITVJ?
D-502MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Tsc2lEPTB;MUiuPFE{QSEQvF2= MV;TRW5ITVJ?
RO82-W-1 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nXTWlEPTB;MUiuPFI5QCEQvF2= MXLTRW5ITVJ?
HuO9 NXXP[2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r4c2lEPTB;MUmuNVM4QSEQvF2= MljlV2FPT0WU
ETK-1 M{L1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF7LkG4Nlch|ryP MnXzV2FPT0WU
SNU-387 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPrTWM2OD1zOT6xPFg6KM7:TR?= MmTWV2FPT0WU
SW1573 NGPqPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\BTWM2OD1zOT6xPVY6KM7:TR?= M1zuU3NCVkeHUh?=
NTERA-S-cl-D1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF7LkKwNFch|ryP MULTRW5ITVJ?
SF126 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi4NWlKSzVyPUG5MlM2ODJizszN Ml7rV2FPT0WU
Calu-3 NGnPfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\4TWM2OD1zOT60NlM4KM7:TR?= MnSzV2FPT0WU
NCI-H1048 NGfCZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HhTWlEPTB;MkCuN|I3PiEQvF2= MVvTRW5ITVJ?
NCI-H226 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJyLkSzPVkh|ryP M33hXHNCVkeHUh?=
FTC-133 M3P1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7qTWM2OD1{MD60O|A{KM7:TR?= NYrQUnhmW0GQR1XS
SF539 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnH[FB6UUN3ME2yNE42OTd{IN88US=> NXHx[GZpW0GQR1XS
TE-6 NXTRV|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjjZZNPUUN3ME2yNE45ODZ5IN88US=> Mn3JV2FPT0WU
UMC-11 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJyLkmxOlQh|ryP NETZTFFUSU6JRWK=
Becker NVS3epN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nuPGlEPTB;MkGuNVEyQCEQvF2= NGXqemNUSU6JRWK=
KP-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknETWM2OD1{MT6xNVk3KM7:TR?= NULUWolHW0GQR1XS
ChaGo-K-1 M{PmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETCSG9KSzVyPUKxMlM3OjdizszN MlHlV2FPT0WU
CFPAC-1 NXrzeWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\4W2VxUUN3ME2yNU4{QDV6IN88US=> MUHTRW5ITVJ?
A498 NV3ZV4M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LkNGlEPTB;MkGuOVMyOiEQvF2= MUXTRW5ITVJ?
NCI-H1755 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe1dplKSzVyPUKxMlY4PDFizszN MXLTRW5ITVJ?
TI-73 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi4NWN{UUN3ME2yNk4{OjhizszN M1LoT3NCVkeHUh?=
NCI-H441 NIDsbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO0VpFEUUN3ME2yNk42Pjh7IN88US=> NF[0U|lUSU6JRWK=
CaR-1 NFHKOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ|LkCyNVMh|ryP MUTTRW5ITVJ?
HCC1806 NXj2RXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XRPGlEPTB;MkOuNFU5OyEQvF2= MXzTRW5ITVJ?
SNU-449 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\a[VNKSzVyPUKzMlMzQSEQvF2= NUS0SFVtW0GQR1XS
EKVX Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3BSJJKSzVyPUKzMlM6ODlizszN MnPDV2FPT0WU
DMS-114 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ|LkW3OlUh|ryP M1rObHNCVkeHUh?=
A704 NW\iRo5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jPTGlEPTB;MkOuOlExOyEQvF2= Mof4V2FPT0WU
LC-2-ad NUXRNGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPGTWM2OD1{Mz62NVQ4KM7:TR?= M1;3enNCVkeHUh?=
VM-CUB-1 NGO5NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ|LkezOFEh|ryP MVfTRW5ITVJ?
PC-3 M4K0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nlTmlEPTB;MkSuNFUzPiEQvF2= NH3DbZhUSU6JRWK=
HEL M4fmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnuS4RmUUN3ME2yOE4xQDZ3IN88US=> NVHaSGhPW0GQR1XS
ABC-1 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnoTWM2OD1{ND6yO|I6KM7:TR?= NYDDT|ZsW0GQR1XS
COLO-680N M{PtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DvVmlEPTB;MkSuOFc3PCEQvF2= NXn2bJE5W0GQR1XS
MZ1-PC NFSzd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj0Vm1LUUN3ME2yOE43QDdizszN NUG0cFNVW0GQR1XS
NCI-H69 M1jBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33wUGlEPTB;MkSuO|M2PCEQvF2= M1;nOXNCVkeHUh?=
TE-1 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zUZZKSzVyPUK1MlA1QTlizszN M2PRPXNCVkeHUh?=
EW-3 NELjZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfLNpNKSzVyPUK1MlEyOyEQvF2= MVTTRW5ITVJ?
PANC-08-13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\UTWM2OD1{NT64NVA{KM7:TR?= MVLTRW5ITVJ?
NMC-G1 NHPSS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly1TWM2OD1{Nj6wNFg5KM7:TR?= M{nUR3NCVkeHUh?=
BT-20 NFraU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ4LkS1OFMh|ryP M2PmXXNCVkeHUh?=
TGBC24TKB M2PxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jVNGlEPTB;Mk[uO|M{OSEQvF2= M1nYbnNCVkeHUh?=
TE-11 M4Dod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPbGlEPTB;Mk[uPVg6PSEQvF2= Mm\QV2FPT0WU
ESS-1 NW\iV|hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ5LkOyNVYh|ryP Mk\pV2FPT0WU
JVM-3 NELU[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrVfFJVUUN3ME2yO{43PDd3IN88US=> MXTTRW5ITVJ?
C3A MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:xOWlEPTB;MkeuPFQ6PiEQvF2= NGP3Xm5USU6JRWK=
MDA-MB-157 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;sZmJKSzVyPUK3Mlg4PTNizszN NYLCdXA{W0GQR1XS
KLE MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHn[GlKSzVyPUK4MlExPThizszN MVHTRW5ITVJ?
ES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHlTWM2OD1{OD6xPFM5KM7:TR?= NIHIdZNUSU6JRWK=
CAL-120 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\0TWM2OD1{OD6zPVk6KM7:TR?= MVPTRW5ITVJ?
NCI-N87 M33Jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HIT2lEPTB;MkiuOVExPSEQvF2= MknOV2FPT0WU
RPMI-8226 NHiwcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDUSXBoUUN3ME2yPU4yQDR|IN88US=> MmTQV2FPT0WU
COR-L88 NFP3bW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTd4hKSzVyPUK5MlI1OTlizszN M1rPRXNCVkeHUh?=
UACC-893 M374[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7LZoVIUUN3ME2yPU4{OTN5IN88US=> M4LtSHNCVkeHUh?=
C8166 NHnKUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzmTWM2OD1{OT65PVk3KM7:TR?= NYe0[o9xW0GQR1XS
J82 M322VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fTVmlEPTB;M{CuPFE1PyEQvF2= M2PGRnNCVkeHUh?=
PFSK-1 NYPGSIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P6dGlEPTB;M{GuNFY2QSEQvF2= MoDtV2FPT0WU
COLO-684 NFjMOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNzLkSzO|Qh|ryP NUnSWo9VW0GQR1XS
CAL-72 M4j6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorLTWM2OD1|MT61O|I6KM7:TR?= NW\Zd|JXW0GQR1XS
SNB75 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1|MT64PVch|ryP NWmxUGtWW0GQR1XS
MDA-MB-415 NH7Hb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNzLkm3OlIh|ryP Mn;DV2FPT0WU
SiHa NYXCNHdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTwTWM2OD1|Mj60O|EyKM7:TR?= NE[yVG1USU6JRWK=
NCI-H1648 M2DaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN{LkmzOFUh|ryP Mn36V2FPT0WU
EFO-21 NWXuXml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonTTWM2OD1|Mz6wNFUh|ryP NFjHSJdUSU6JRWK=
HCC38 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTN|LkO4OFEh|ryP MVHTRW5ITVJ?
IA-LM MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfrUVBKSzVyPUOzMlc5QDlizszN MWPTRW5ITVJ?
CTV-1 M4P4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknuTWM2OD1|Mz65O|g3KM7:TR?= NGXS[2tUSU6JRWK=
NCI-H446 NUHIRZdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzZZo9bUUN3ME2zOE4zPjh7IN88US=> MnO5V2FPT0WU
IST-SL1 M2f1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN2Lke0NFgh|ryP M4jrbXNCVkeHUh?=
EW-22 NHPRWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqVYQ6UUN3ME2zOE44PzV7IN88US=> MVLTRW5ITVJ?
JEG-3 NIDWV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN4LkG3OlYh|ryP Mn\KV2FPT0WU
LU-65 M3q0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj2dIFKSzVyPUO2MlI6QDVizszN MXrTRW5ITVJ?
NCI-H596 NVPRVHVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXjTWM2OD1|Nj65OVkyKM7:TR?= Mn7xV2FPT0WU
KNS-81-FD NX34ZYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3nNG5KSzVyPUO3MlE1PSEQvF2= M3TE[HNCVkeHUh?=
NCI-H1793 M1rXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfKTWM2OD1|Nz63NFg3KM7:TR?= M1XHTnNCVkeHUh?=
NCI-H460 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN6LkC4O|Mh|ryP NYe2NJdXW0GQR1XS
MPP-89 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDV[GZKSzVyPUO5MlU5QDZizszN Mle5V2FPT0WU
D-542MG M{PPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTN7Lki0N|Yh|ryP MlrqV2FPT0WU
JAR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrpPGZKSzVyPUSwMlQ4ODVizszN MmfqV2FPT0WU
NCI-H209 NGmzWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH73SpZKSzVyPUSwMlY4PyEQvF2= NIe4TpFUSU6JRWK=
G-402 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3LTWM2OD12MT6zPVk{KM7:TR?= MX7TRW5ITVJ?
IST-MES1 NX24fGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnUUWJKSzVyPUSyMlE6OzVizszN NEPEdY5USU6JRWK=
Daoy MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR{LkW0O|Eh|ryP M3zUPXNCVkeHUh?=
EW-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPmTWM2OD12Mz6xNlEyKM7:TR?= NVHtPFNlW0GQR1XS
Saos-2 NX7aZ5ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnxNIlkUUN3ME20N{4yPTN5IN88US=> M4G4N3NCVkeHUh?=
no-10 NELRO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULISHFCUUN3ME20N{4yPzB{IN88US=> M3fVZXNCVkeHUh?=
HCC1395 NEC0dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[1[2lEPTB;NEOuOFY1PCEQvF2= NX7SbFBUW0GQR1XS
HCE-4 NFK0TI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHYWGZKSzVyPUSzMlc3PjRizszN MUPTRW5ITVJ?
EW-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36xSGlEPTB;NEOuPFA1QSEQvF2= M{nVNXNCVkeHUh?=
OCUB-M NWH0PHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7aNoVKSzVyPUS0MlM3OzhizszN MnT3V2FPT0WU
IGR-1 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ES4g4UUN3ME20OE41OTF3IN88US=> M2TCfHNCVkeHUh?=
NCI-H1838 NVHpUlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnRfHB[UUN3ME20OE41OzR7IN88US=> M3zLdnNCVkeHUh?=
NCI-H2405 NGOxfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LpOWlEPTB;NESuOVM1KM7:TR?= MWPTRW5ITVJ?
GB-1 NWX4eGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrpTWM2OD12ND63OFY{KM7:TR?= MmPVV2FPT0WU
MG-63 M{HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPFTWM2OD12Nj6wOlk3KM7:TR?= MWHTRW5ITVJ?
KP-N-YN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHmb3pKSzVyPUS2MlQ3PzlizszN NFTsb29USU6JRWK=
no-11 NF;4dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X1XWlEPTB;NEeuNFI1PCEQvF2= NXLqOYpwW0GQR1XS
SW948 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjDW|ZKSzVyPUS3MlM{PzdizszN NVrOWmQ{W0GQR1XS
CAMA-1 M37IOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYThbGwzUUN3ME20O{4{PDN6IN88US=> M3LBR3NCVkeHUh?=
HCC1187 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD12Nz61NUDPxE1? MYHTRW5ITVJ?
D-392MG NGTBV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370bGlEPTB;NEeuOlUyPiEQvF2= NVHTcG1nW0GQR1XS
647-V MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR7LkO0NVQh|ryP NXjobG5oW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID